Related references
Note: Only part of the references are listed.Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial
Chun-Yuan Lin et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2017)
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
Akiko Matsuura et al.
ACTA NEUROPSYCHIATRICA (2015)
Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods
Tomasz Pawelczyk et al.
BMC PSYCHIATRY (2015)
Antipsychotic medication in schizophrenia: a review
John Lally et al.
BRITISH MEDICAL BULLETIN (2015)
Sarcosine-Based Glycine Transporter Type-1 (GlyT-1) Inhibitors Containing Pyridazine Moiety: A Further Search for Drugs with Potential to Influence Schizophrenia Negative Symptoms
Laszlo G. Harsing et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Inhibition of Glycine Transporter 1: The Yellow Brick Road to New Schizophrenia Therapy?
Philipp Singer et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Pharmacological treatment of negative symptoms in schizophrenia
Hans-Jurgen Moeller et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2015)
Effects of sodium benzoate, a widely used food preservative, on glucose homeostasis and metabolic profiles in humans
Belinda S. Lennerz et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia
Dominik Strzelecki et al.
NUTRIENTS (2015)
Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine
Akiko Matsuura et al.
ACTA NEUROPSYCHIATRICA (2015)
D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial
Joshua T. Kantrowitz et al.
LANCET PSYCHIATRY (2015)
Drug models of schizophrenia
Hannah Steeds et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2015)
Cyclodextrins, Blood-Brain Barrier, and Treatment of Neurological Diseases
Miklos Vecsernyes et al.
ARCHIVES OF MEDICAL RESEARCH (2014)
Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia A Randomized, Double-Blind, Proof-of-Concept Study
Daniel Umbricht et al.
JAMA PSYCHIATRY (2014)
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Scott W. Woods et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Add-on Treatment of Benzoate for Schizophrenia A Randomized, Double-blind, Placebo-Controlled Trial of D-Amino Acid Oxidase Inhibitor
Hsien-Yuan Lane et al.
JAMA PSYCHIATRY (2013)
A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E plus C in schizophrenia
H. Bentsen et al.
TRANSLATIONAL PSYCHIATRY (2013)
Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists
Thomas Papouin et al.
CELL (2012)
Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophrenia
Andrea Balla et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
Mark Weiser et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Twenty-five Years of Glutamate in Schizophrenia: Are We There Yet?
Daniel C. Javitt
SCHIZOPHRENIA BULLETIN (2012)
Schizophrenia: Redox Regulation and Volume Neurotransmission
I. Bokkon et al.
CURRENT NEUROPHARMACOLOGY (2011)
Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain
Christine A. Strick et al.
NEUROPHARMACOLOGY (2011)
High dose D-serine in the treatment of schizophrenia
Joshua T. Kantrowitz et al.
SCHIZOPHRENIA RESEARCH (2010)
Co-Administration of a D-Amino Acid Oxidase Inhibitor Potentiates the Efficacy of D-Serine in Attenuating Prepulse Inhibition Deficits After Administration of Dizocilpine
Kenji Hashimoto et al.
BIOLOGICAL PSYCHIATRY (2009)
Redox dysregulation, neurodevelopment, and schizophrenia
Kim Q. Do et al.
CURRENT OPINION IN NEUROBIOLOGY (2009)
The Behavioral and Neurochemical Effects of a Novel D-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and D-Serine
Sean M. Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatum
Andrea Balla et al.
NEUROPHARMACOLOGY (2009)
In vitro and in vivo pharmacological profile of AS057278, a selective D-amino acid oxidase inhibitor with potential anti-psychotic properties
Tiziana Adage et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
Increased brain D-amino acid oxidase (DAAO) activity in schizophrenia
Caroline Madeira et al.
SCHIZOPHRENIA RESEARCH (2008)
The impact of ω-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol:: An open-label pilot study
E. Y. Sivrioglu et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2007)
Extracellular ascorbate modulates glutamate dynamics: role of behavioral activation
Michael I. Sandstrom et al.
BMC NEUROSCIENCE (2007)
Preliminary evidence for a link between schizophrenia and NMDA-glycine site receptor ligand metabolic enzymes, D-amino acid oxidase (DAAO) and kynurenine aminotransferase-1 (KAT-1)
Ranjna Kapoor et al.
BRAIN RESEARCH (2006)
Modulation of striatal dopamine release in vitro by agonists of the glycineB site of NMDA receptors;: interaction with antipsychotics
S Bennett et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia
T Sumiyoshi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2005)
Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type
G Neeman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Modulation of striatal dopamine release by glycine transport inhibitors
DC Javitt et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Inhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action
DC Javitt et al.
MOLECULAR PSYCHIATRY (2005)
Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms
T Sumiyoshi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2004)
Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists
DC Javitt et al.
NEUROPSYCHOPHARMACOLOGY (2004)
D-Serine-induced nephrotoxicity: possible interaction with tyrosine metabolism
RE Williams et al.
TOXICOLOGY (2004)
The glycine transporter-1 inhibitors NFPS and Org 24461: a pharmacological study
LG Harsing et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2003)
Allosteric regulation of mouse brain serine racemase
A Neidle et al.
NEUROCHEMICAL RESEARCH (2002)
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
LS Kegeles et al.
BIOLOGICAL PSYCHIATRY (2000)
Inhibition of striatal dopamine release by glycine and glycyldodecylamide
DC Javitt et al.
BRAIN RESEARCH BULLETIN (2000)
Share Paper
